ClinicalTrials.gg
Sign In

Neurofibromatoses clinical trials

The registry lists 57 studies for Neurofibromatoses across more than 10 countries. 14 are recruiting or about to start. 23 of them are mainly about Neurofibromatoses (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29. Counting its 2 narrower conditions too, such as Neurofibromatosis 1: 247 studies, 58 open.

Get an email when these change. Save the Neurofibromatoses studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
32
Recruiting
10
Terminated
5
Not yet recruiting
3
Status unknown
3
Active, not recruiting
2

Phase

Phase 2
15
Phase 1
9
Early Phase 1
2
Phase 3
2
Phase 4
1

Where

United States
41
Germany
4
United Kingdom
2
China
2
Australia
2
France
2

Who runs them

Massachusetts General Hospital (8) · National Cancer Institute (NCI) (5) · Indiana University (3) · Johns Hopkins University (2) · Memorial Sloan Kettering Cancer Center (2) · University of Alabama at Birmingham (2) · Assistance Publique - Hôpitaux de Paris (2) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (2)

What is being tested here

Drugs under test in Neurofibromatoses studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Mirdametinib102
Talimogene laherparepvec101
Imatinib013
Sunitinib002
Binimetinib001
Diphenylcyclopropenone001
Cabozantinib001
Aminolevulinic Acid001
Dexmedetomidine001
Tipifarnib001

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 9

Coming up

0phase 3 studies under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 10 Neurofibromatoses studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stop at 75 or younger. 3 (30%) take children under 18. 1 (10%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 10
AgeWomenMen
103 (30%)3 (30%)
1810 (100%)9 (90%)
3010 (100%)9 (90%)
4010 (100%)9 (90%)
5010 (100%)9 (90%)
6510 (100%)9 (90%)
7510 (100%)9 (90%)
859 (90%)8 (80%)

Across all 57 studies, recruiting or not: 35% stop at 75 or younger and 28% at 65; 58% take children; 2% are for women only and 0% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 57. Browse all 57 → or search them.